Strong Second-Half Momentum Drives 85% Net Loss Improvement; FDA Clearance Secured for Innovative Fusionâ„¢ Biomaterial Implant; Board Rejects Undervalued Acquisition Interest

CANTON, Conn., March 16, 2026 /PRNewswire/ -- Kelyniam Global (OTC: KLYG), a leader in custom cranial implants, today announced its financial results for the year ended December 31, 2025.

Recommended for you